Great news! The Tallomak clinical trial is now fully enrolled. Enrollment is the number of participants in a clinical trial. Researchers target a certain number of participants needed for their study and being fully enrolled means they have met their number and are no longer recruiting.
An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of lacutamab (IPH4102) alone or in combination with chemotherapy in patients with advanced t-cell lymphoma
Clinical Trial Name: IPH4102-201 / TELLOMAK study
Clinical Trial Description:
The trial is an open label, multi-cohort and multi-center phase II. It is designed to include a total of 3 cohorts, 1 cohort for Sézary syndrome (SS) patients (Cohort 1) and 2 cohorts for mycosis fungoides (MF) patients (Cohorts 2-3). All patients will be treated with lacutamab (IPH4102) in monotherapy. For MF patients (Cohorts 2 and 3), central testing on the protein KIR3DL2 will be performed to inform on cohort allocation.
Purpose
The purpose of this study is to evaluate the effectiveness and safety of a new experimental drug named lacutamab. Lacutamab is a monoclonal antibody that targets the protein KIR3DL2 and was shown to deplete the cells that express the receptor. Lacutamab was previously administered in a previous clinical study that included 44 patients, of whom 35 had SS and 8 had MF. It was shown to be safe. Preliminary results suggest that it is associated with encouraging clinical activity in patients with SS. Very few MF patients were previously treated with lacutamab to inform on its effectiveness. This study aims to confirm the clinical activity of lacutamab in SS and inform on its potential efficacy and safety in MF.
Drs. Pierluigi Porcu and Martine Bagot discuss the history of lacutamab (TELLOMAK) for treating CTCL and provide an update on the phase two clinical trial. Hear from the original researchers on how it started and where it is now.
Researchers
Pierluigi Porcu, MD
Professor of Medical
Oncology, Dermatology, and Cutaneous Biology Director, Division of Hematologic Malignancies
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania
Martine Bagot, PhD
Professor and Head of Department of Dermatology
Hôpital Saint Louis
Paris, France
A panel discussion about the TELLOMAK clinical trial evaluating lacutamab in patients with advanced T-cell lymphomas, including Sézary syndrome and mycosis fungoides. Dr. Youn Kim and Dr. Joyson Karakunnel join Susan Thornton to discuss the clinical perspective of the study, where the study is today, preliminary data to share from the trial and more.
Panelists:
Joyson Karakunnel, MD, MSc, FACP, Innate Pharma
Youn Kim, MD, Stanford Health Care
Susan Thornton, CEO, Cutaneous Lymphoma Foundation